Prevention of postmenopausal bone loss and endometrial responses during a two year prospective study with transdermal 17 beta-estradiol and oral medroxyprogesterone acetate

MeSH terms

• Administration, Cutaneous
• Administration, Oral
• Antineoplastic Agents / administration & dosage
• Antineoplastic Agents / pharmacology
• Antineoplastic Agents / therapeutic use*
• Endometrium / drug effects*
• Endometrium / physiology
• Estradiol / administration & dosage
• Estradiol / pharmacology
• Estradiol / therapeutic use*
• Female
• Humans
• Medroxyprogesterone / administration & dosage
• Medroxyprogesterone / analogs & derivatives*
• Medroxyprogesterone / pharmacology
• Medroxyprogesterone / therapeutic use
• Medroxyprogesterone Acetate
• Middle Aged
• Osteoporosis / drug therapy
• Osteoporosis / prevention & control*